Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Roflumilast in Moderate to Severe Psoriasis
NCT07233291Phase 2Recruiting
- Start
- Aug 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roflumilast in plaque psoriasis. Started Aug 2025; status: recruiting.
02
Drugs
roflumilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07233291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233291.